Browse
Submit Data
Databases
API
Help

Dataset Information

30 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multicenter Phase II study of rechallenge Cetuximab plus Irinotecan in heavily pretreated Wild type KRAS metastatic Colorectal cancer

ABSTRACT: Interventions: Cetuximab + Irinotecan therapy Cetuximab Weekly schedule 400mg/(initial dose):250mg/m2(Maintenance dose) every week or Bi-weekly schedule 500mg/m2 every 2 weeks Irinotecan 150mg/m2 every 2 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2625919 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: cetuximab (first time) 400mg/m2/week, cetuximab (after 2nd time) 250mg/m2/week, irinotecan 150mg/m2/bi-weekly Primary outcome(s): 3-Month Progression Free Survival Rate Study Design: Single arm Non-randomized

| 2626020 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

Shankaran2018 - Systems Pharmacology Model of Gastrointestinal Damage

Project description:Model predicted time course of enterocyte loss in patients treated with weekly doses matched observed AE profiles. The model also correctly predicts a lower level of AEs for every 3 weeks (Q3W), as compared to the weekly schedule.

2021-10-26 | MODEL2110260001 | BioModels

Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancer

Project description:Interventions: FOLFOXIRI+cetuximab (until 12 courses) Cetuximab 400mg/m2/weekly (initial dose) 250mg/m2/weekly (maintenance) Irinotecan 100-150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Recommended dose Study Design: Single arm Non-randomized

| 2630948 | ecrin-mdr-crc

Early tumor shrinkage of Cetuximab and mFOLFOX6 in RAS-wild type unresectable metastatic colorectal cancer.

Project description:Interventions: Weekly Cetuximab+mFOLFOX6 Cetuximab 400mg/m2/ initial 250mg/m2/ qw Oxaliplatin 85mg/m2/ qw l-LV 200mg/m2/ qw 5FU-bols 400mg/m2/ qw 5FU-infusional 2,400mg/m2/ qw OR Biweekly Cetuximab+mFOLFOX6 Cetuximab 500mg/m2/ q2w Oxaliplatin 85mg/m2/ q2w l-LV 200mg/m2/ q2w 5FU-bols 400mg/m2/ q2w 5FU-infusional 2,400mg/m2/ q2w Primary outcome(s): ETS(Early Tumor Shrinkage) rate Study Design: Single arm Non-randomized

| 2630670 | ecrin-mdr-crc

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.

Project description:This 2 arm study will assess the efficacy and safety of Avastin in combination with irinotecan + 5-fluorouracil/folinic acid, versus irinotecan + fluorouracil/folinic acid alone, as first line treatment in Chinese patients with metastatic colorectal cancer. Patients will be randomized 2:1 to receive 6-weekly cycles of Avastin (5mg/kg iv every 2 weeks) + irinotecan 125mg/m2 iv / leucovorin 20mg/m2 iv / fluorouracil 500mg/m2 iv weekly for 4 weeks, or 6-weekly cycles of irinotecan 125mg/m2 iv / leucovorin 20mg/m2 iv / fluorouracil 500mg/m2 iv weekly for 4 weeks. The anticipated time on study treatment is until disease progression, and the sample size is 100-500 individuals.

| 2052695 | ecrin-mdr-crc

transCONFIRM gene expression analysis

Project description:gene expression analysis ussing microarray analysis of a subset of primary tumors collected from patients that participated in the CONFIRM phase III study, which randomized post menopausal patients with ER+ metastatic breast cancer to fulvestrant 500mg and fulvestrant 250mg.

2015-12-16 | GSE76040 | GEO

Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer

Project description:Interventions: Capecitabine+oxaliplatin(XELOX)+Cetuximab Cetuximab loading dose 400mg/m2, 250mg/m2/week or 500mg/m2/2weeks Capecitabine 2000mg/m2(day1-7)/2weeks Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2622614 | ecrin-mdr-crc

transCONFIRM gene expression analysis

2015-12-16 | E-GEOD-76040 | biostudies-arrayexpress

Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive advanced and/or metastatic colorectal cancer, evaluation of the safety and efficacy based on KRAS mutation status (T-CORE0801)

Project description:Interventions: cetuximab 400 mg/m2 given as 2 hours infusion for the first time, 250mg/m2 as 1 hour infusion for the second time or later. Irinotecan 100mg/m2 repeated every week followed by one week rest or Irinotecan 150mg/m2 repeated every two weeks. Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2617157 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data